NEW YORK, March 13, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Adeptus Health Inc. ("Adeptus Health Inc.") (NYSE:ADPT) between April 29, 2016 and March 1, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas, Tyler Division. To get more information go to:
http://www.zlk.com/pslra-sa/adeptus-health-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Adeptus had material weaknesses in its internal control over financial reporting in the areas of revenue recognition, accounts receivable, accounting for a contribution to an unconsolidated joint venture, and accounting for equity in (loss) earnings of unconsolidated joint ventures; and (2) as a result, defendants’ statements about Adeptus’ business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Adeptus Health Inc. you have until May 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 



